Barclays PLC Has $7.17 Million Stock Position in Globus Medical, Inc. (NYSE:GMED)

Barclays PLC lessened its position in shares of Globus Medical, Inc. (NYSE:GMED - Free Report) by 6.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,683 shares of the medical device company's stock after selling 5,918 shares during the quarter. Barclays PLC owned about 0.06% of Globus Medical worth $7,169,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new position in Globus Medical in the fourth quarter valued at approximately $27,000. UMB Bank n.a. boosted its stake in Globus Medical by 60.2% during the 4th quarter. UMB Bank n.a. now owns 548 shares of the medical device company's stock worth $45,000 after acquiring an additional 206 shares during the last quarter. V Square Quantitative Management LLC grew its holdings in Globus Medical by 52.0% during the fourth quarter. V Square Quantitative Management LLC now owns 576 shares of the medical device company's stock valued at $48,000 after purchasing an additional 197 shares during the period. First Horizon Advisors Inc. raised its holdings in Globus Medical by 24.7% in the fourth quarter. First Horizon Advisors Inc. now owns 666 shares of the medical device company's stock worth $55,000 after purchasing an additional 132 shares during the period. Finally, Huntington National Bank grew its holdings in shares of Globus Medical by 47.8% in the 4th quarter. Huntington National Bank now owns 958 shares of the medical device company's stock valued at $79,000 after buying an additional 310 shares during the period. Institutional investors own 95.16% of the company's stock.

Globus Medical Price Performance

NYSE:GMED traded up $0.46 during trading hours on Tuesday, hitting $73.08. The company's stock had a trading volume of 318,839 shares, compared to its average volume of 1,037,810. The stock has a fifty day simple moving average of $74.07 and a 200-day simple moving average of $80.17. Globus Medical, Inc. has a twelve month low of $49.33 and a twelve month high of $94.93. The company has a market capitalization of $10.05 billion, a P/E ratio of 97.43, a PEG ratio of 1.61 and a beta of 1.28.

Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.10. Globus Medical had a net margin of 4.09% and a return on equity of 10.83%. The firm had revenue of $657.29 million for the quarter, compared to analysts' expectations of $646.19 million. On average, equities analysts predict that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

GMED has been the subject of several recent analyst reports. Canaccord Genuity Group increased their price target on Globus Medical from $92.00 to $101.00 and gave the stock a "buy" rating in a report on Friday, January 10th. Stifel Nicolaus upped their price target on shares of Globus Medical from $92.00 to $94.00 and gave the company a "buy" rating in a report on Friday, February 21st. Wells Fargo & Company cut their price objective on shares of Globus Medical from $95.00 to $93.00 and set an "overweight" rating on the stock in a research report on Friday, February 21st. Barclays lifted their price target on Globus Medical from $100.00 to $103.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Finally, Truist Financial decreased their price objective on Globus Medical from $82.00 to $80.00 and set a "hold" rating for the company in a report on Friday, April 11th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $96.91.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.